Launched in April 2022, Cellistic specializes in process development and manufacture of cell therapies based on human induced pluripotent stem cell (iPSC) technology. The company’s focus and expertise in iPSC generation and differentiation protocol development makes it well-positioned to partner with innovative cell therapy developers to establish novel advanced therapies. With more than a decade of scientific and technical knowledge transfer from sister company Ncardia, Cellistic is uniquely experienced in designing and optimizing manufacturing procedures for iPSCs that deliver quality products at scale. 

For more information, visit www.cellistic.com. 


Biotechnology

Life Sciences

Therapeutics

Cellistic

Cellistic's headquarters in Mont-Saint-Guibert, Belgium

Description

People (3)

Jobs (0)

Other offices